Media Articles Related to Azilect (Rasagiline)
TBI Patients at Risk for Parkinson's Disease: Psychiatric Times and Neurology Times
Source: MedPage Today Cardiovascular [2015.07.28]
(MedPage Today) -- Also: big news for neuroimmunology, and stroke patients rehabilitate with tech
Parkinson's disease risk 'lowered by diabetes drug'
Source: Biology / Biochemistry News From Medical News Today [2015.07.23]
Diabetes patients treated with glitazone have a lower risk of developing Parkinson's disease, suggesting the target of the drug could be a fruitful target for the condition.
Parkinson's disease may be treatable with antimalaria drugs
Source: Biology / Biochemistry News From Medical News Today [2015.07.17]
Breakthrough study shows existing malaria drugs directly activate the brain receptor Nurr1 and significantly reduce Parkinson's behavior in rats without inducing dyskinesia.
Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet amantadine Specialty [2015.02.20]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 2/20/2015 4:38:06 PM
Scripps Florida scientists' 'mad cow' discovery points to possible neuron killing mechanism behind Alzheimer's and Parkinson's diseases
Source: CJD / vCJD / Mad Cow Disease News From Medical News Today [2015.02.16]
Scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time discovered a killing mechanism that could underpin a range of the most intractable...
Published Studies Related to Azilect (Rasagiline)
Rasagiline treatment effects on parkinsonian tremor. 
Tremor is a common symptom of Parkinson's disease (PD). The underlying
pathophysiology of parkinsonian rest tremor is not well understood... These
data suggest that rasagiline used as monotherapy and as adjunctive therapy is
effective for reducing tremor severity in patients with PD.
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. [2011.05]
BACKGROUND: The ADAGIO study investigated whether rasagiline has disease-modifying effects in Parkinson's disease. Rasagiline 1 mg per day, but not 2 mg per day, was shown to be efficacious in the primary analysis. Here, we report additional secondary and post-hoc analyses of the ADAGIO study... INTERPRETATION: These findings show that rasagiline delayed the need for symptomatic antiparkinsonian drugs and emphasise the contribution of the UPDRS ADL in the response of the rasagiline 1 mg per day early-start versus delayed-start group. The rate of UPDRS deterioration was less than was anticipated from previous studies and correlated with baseline severity. Understanding of the pattern of UPDRS deterioration is essential to assess disease modification. FUNDING: Teva Pharmaceutical Industries and H Lundbeck A/S. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
Rasagiline is a selective, monoamine oxidase (MAO)-B inhibitor indicated for treatment of Parkinson's disease. This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days...
Long-term efficacy of rasagiline in early Parkinson's disease. [2010.06]
This study was designed to follow the long-term efficacy, safety, and tolerability of rasagiline for Parkinson's disease (PD) with data collected from all patients who had ever taken rasagiline during the 12-month TEMPO monotherapy trial (N = 398) and subsequent open-label extension... Rasagiline therapy for PD was effective, well tolerated, and safe in this long-term trial.
The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive.The recently completed delayed-start ADAGIO (Attenuation of Disease Progression with Azilect Given Once-daily) trial suggests a potential disease-modifying effect for rasagiline 1 mg/day, though the clinical import of this finding has yet to be established.
Clinical Trials Related to Azilect (Rasagiline)
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease [Completed]
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at
their first visit based on the drugs they are taking for their PD:
- Group 1 Patients using Azilect and no other therapy.
- Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or
Study to Evaluate the Effects of Azilect® on Sleep Disturbances in Parkinson's Disease [Recruiting]
Study of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations [Recruiting]
To evaluate the efficacy of a fixed dose of rasagiline (1 mg/day) vs placebo as assessed by
the change from baseline in mean total daily OFF time during 18 weeks of treatment in
levodopa-treated Parkinson's Disease (PD) patients with motor fluctuations.
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn [Recruiting]
The primary endpoint for this study is the clinical response after 12 weeks of treatment,
defined as a change in total score from baseline depressive symptoms as measured by the Beck
Depression Inventory-Amended (BDI-IA) total score.
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients [Recruiting]
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease
even in the earliest stages of the disease. There have been no treatments that have been
proven to improve sense of smell in patients with Parkinson's Disease.
Rasagiline (brand name: Azilect) was approved by the U. S. Food and Drug Administration (FDA)
on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated
with the disease. The purpose of this study is to see if there is change in sense of smell
after starting Rasagiline.
Reports of Suspected Azilect (Rasagiline) Side Effects
Drug Interaction (14),
Confusional State (8), more >>